PARP inhibitor and immune checkpoint inhibitor may have synergism efficacy in gallbladder cancer
Yu Chen,
Xudong Fan,
Ruohuang Lu
et al.
Abstract:Background
Gallbladder cancer (GBC) is aggressive with poor prognosis. PARP inhibitors (PARPi) targets PARP enzymes, showing efficacy in BRCA-mutated patients. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has transformed cancer treatment. Yet, the combined impact of PARPi and ICIs in GBC is unclear.
Methods
We presented a groundbreaking case of a GBC patient with BRCA2 mutations receiving PARPi and ICIs combination therapy after failing multiple-line treatments. NGS-Seq identified BRCA gene… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.